LDS/Medical Tests/Macrolide Resistance of Mycoplasma genitalium

Macrolide Resistance of Mycoplasma genitalium

Mycoplasma genitalium is a sexually transmitted bacterium implicated in 15% to 20% of non-gonococcal urethritis cases. It is also a major cause of cervicitis and pelvic inflammatory disease (PID) in women. One challenge in laboratory diagnosis is that M. genitalium cannot be cultured using routine microbiological techniques and requires specialized media with Vero cell lines for growth.

A key characteristic of M. genitalium is the absence of a cell wall, which makes it inherently resistant to beta-lactam antibiotics and other agents targeting peptidoglycan synthesis. Despite this, the organism is generally susceptible to macrolides, tetracyclines, and fluoroquinolones. Among these, macrolides, particularly azithromycin, have been considered first-line therapy.

However, emerging global data indicates a significant rise in macrolide resistance. This resistance is largely due to point mutations in domain V of the 23S rRNA gene, especially the A2058G, A2059G, and A2058T mutations (E. coli numbering). These mutations reduce the binding affinity of macrolides to the bacterial ribosome, rendering the drugs ineffective. Because routine culture and susceptibility testing are not feasible for M. genitalium, treatment decisions are often empiric. The increasing prevalence of resistance underscores the importance of targeted molecular testing to identify macrolide resistance mutations prior to treatment initiation. Real-time PCR assays that detect these specific mutations are now used to guide therapy and reduce treatment failure and resistance selection.

  • For the detection of macrolide resistance in M. genitalium
  • Guides antibiotic selection and improves treatment efficacy
  • Supports antimicrobial stewardship by avoiding ineffective therapy
A positive result indicates the presence of 23S rRNA mutations associated with macrolide resistance. Macrolide antibiotics should be avoided, and alternative treatments such as moxifloxacin should be considered. A negative result indicates the absence of resistance-associated mutations. Macrolide therapy is likely to be effective in such cases

Negative (Not Detected)

Real-time polymerase chain reaction (PCR).

Urethral swab, cervical swab, endometrial swab, urine, (iquid cytology (ThinPrep, SurePath).

Stability

Swab/urine

  • Ambient: 1-3days.
  • Refrigerated: 3-5 days
  • Frozen: 1 month

Liquid cytology is stable for 30 days at room temperature.

Chlamydia trachomatis, Neisseria gonorrhoea, STI panel, HIV, CRP, Treponema pallidum antibody, urinalysis.
1 to 4 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login